Stock Track | Xeris Pharmaceuticals Plunges 6.79% Pre-market on Q3 Revenue Miss and Updated Guidance

Stock Track11-06

Xeris Pharmaceuticals Inc (XERS) shares tumbled 6.79% in pre-market trading on Thursday, as investors reacted to the company's third-quarter earnings report and updated revenue guidance for 2025.

The biopharmaceutical company reported Q3 product revenue of $74.063 million, slightly missing the IBES estimate of $74.2 million. Despite the revenue shortfall, Xeris managed to post a net income of $621,000 for the quarter, translating to earnings per share of $0. The company also reported an operating income of $6.731 million, indicating improved operational efficiency.

Adding to investor concerns, Xeris Biopharma Holdings Inc updated its 2025 revenue guidance to a range of $285-$290 million. While the specific previous guidance was not mentioned in the available news, the market reaction suggests that this updated forecast may be lower than earlier expectations. The combination of the slight Q3 revenue miss and the potentially lowered future guidance appears to have triggered the significant pre-market sell-off.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1156774454?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156774454","market":"sg","top_or_hot":-1,"title":"Stock Track | Xeris Pharmaceuticals Plunges 6.79% Pre-market on Q3 Revenue Miss and Updated Guidance","media":"Stock Track","content":"<p>Xeris Pharmaceuticals Inc (XERS) shares tumbled 6.79% in pre-market trading on Thursday, as investors reacted to the company's third-quarter earnings report and updated revenue guidance for 2025.</p>\n\n<p>The biopharmaceutical company reported Q3 product revenue of $74.063 million, slightly missing the IBES estimate of $74.2 million. Despite the revenue shortfall, Xeris managed to post a net income of $621,000 for the quarter, translating to earnings per share of $0. The company also reported an operating income of $6.731 million, indicating improved operational efficiency.</p>\n\n<p>Adding to investor concerns, Xeris Biopharma Holdings Inc updated its 2025 revenue guidance to a range of $285-$290 million. While the specific previous guidance was not mentioned in the available news, the market reaction suggests that this updated forecast may be lower than earlier expectations. The combination of the slight Q3 revenue miss and the potentially lowered future guidance appears to have triggered the significant pre-market sell-off.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Xeris Pharmaceuticals Plunges 6.79% Pre-market on Q3 Revenue Miss and Updated Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Xeris Pharmaceuticals Plunges 6.79% Pre-market on Q3 Revenue Miss and Updated Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-06 20:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Xeris Pharmaceuticals Inc (XERS) shares tumbled 6.79% in pre-market trading on Thursday, as investors reacted to the company's third-quarter earnings report and updated revenue guidance for 2025.</p>\n\n<p>The biopharmaceutical company reported Q3 product revenue of $74.063 million, slightly missing the IBES estimate of $74.2 million. Despite the revenue shortfall, Xeris managed to post a net income of $621,000 for the quarter, translating to earnings per share of $0. The company also reported an operating income of $6.731 million, indicating improved operational efficiency.</p>\n\n<p>Adding to investor concerns, Xeris Biopharma Holdings Inc updated its 2025 revenue guidance to a range of $285-$290 million. While the specific previous guidance was not mentioned in the available news, the market reaction suggests that this updated forecast may be lower than earlier expectations. The combination of the slight Q3 revenue miss and the potentially lowered future guidance appears to have triggered the significant pre-market sell-off.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XERS","symbol_name":"Xeris制药","start_time":0,"source_url":"","article_id":"1156774454","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156774454","pubTimestamp":1762430803,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Xeris Pharmaceuticals Inc (XERS) shares tumbled 6.79% in pre-market trading on Thursday, as investors reacted to the company's third-quarter earnings report and updated revenue guidance for 2025....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XERS":"Xeris制药"},"translate_title":"个股追踪|Xeris Pharmaceuticals盘前暴跌6.79%因Q3营收未达预期及指引更新","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XERS":1},"content_text":"Xeris Pharmaceuticals Inc (XERS) shares tumbled 6.79% in pre-market trading on Thursday, as investors reacted to the company's third-quarter earnings report and updated revenue guidance for 2025.\nThe biopharmaceutical company reported Q3 product revenue of $74.063 million, slightly missing the IBES estimate of $74.2 million. Despite the revenue shortfall, Xeris managed to post a net income of $621,000 for the quarter, translating to earnings per share of $0. The company also reported an operating income of $6.731 million, indicating improved operational efficiency.\nAdding to investor concerns, Xeris Biopharma Holdings Inc updated its 2025 revenue guidance to a range of $285-$290 million. While the specific previous guidance was not mentioned in the available news, the market reaction suggests that this updated forecast may be lower than earlier expectations. The combination of the slight Q3 revenue miss and the potentially lowered future guidance appears to have triggered the significant pre-market sell-off.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156774454","isCrawlerRequest":true}